BG106192A - Аминоазацикли, заместени с хетероцикъл, полезни като средства за контролиране на централната нервнасистема - Google Patents

Аминоазацикли, заместени с хетероцикъл, полезни като средства за контролиране на централната нервнасистема Download PDF

Info

Publication number
BG106192A
BG106192A BG106192A BG10619201A BG106192A BG 106192 A BG106192 A BG 106192A BG 106192 A BG106192 A BG 106192A BG 10619201 A BG10619201 A BG 10619201A BG 106192 A BG106192 A BG 106192A
Authority
BG
Bulgaria
Prior art keywords
pyridinyl
mmol
chloro
methyl
amine
Prior art date
Application number
BG106192A
Other languages
Bulgarian (bg)
English (en)
Inventor
Michael Schrimpf
Kevin Sippy
Jerome Daanen
Keith Ryther
Jianguo Ji
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/559,881 external-priority patent/US6833370B1/en
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of BG106192A publication Critical patent/BG106192A/bg

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BG106192A 1999-05-21 2001-12-07 Аминоазацикли, заместени с хетероцикъл, полезни като средства за контролиране на централната нервнасистема BG106192A (bg)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31670799A 1999-05-21 1999-05-21
US09/559,881 US6833370B1 (en) 1999-05-21 2000-04-26 Heterocycle substituted aminoazacycles useful as central nervous system agents
PCT/US2000/013339 WO2000071534A1 (en) 1999-05-21 2000-05-15 Heterocyclic substituted aminoazacycles useful as central nervous system agents

Publications (1)

Publication Number Publication Date
BG106192A true BG106192A (bg) 2002-08-30

Family

ID=26980553

Family Applications (1)

Application Number Title Priority Date Filing Date
BG106192A BG106192A (bg) 1999-05-21 2001-12-07 Аминоазацикли, заместени с хетероцикъл, полезни като средства за контролиране на централната нервнасистема

Country Status (24)

Country Link
EP (2) EP1428824A1 (pt)
JP (1) JP2003500402A (pt)
KR (2) KR100714121B1 (pt)
CN (2) CN1192028C (pt)
AT (1) ATE270288T1 (pt)
AU (1) AU781241B2 (pt)
BG (1) BG106192A (pt)
BR (1) BR0007229A (pt)
CA (1) CA2373793A1 (pt)
CZ (1) CZ20014127A3 (pt)
DE (1) DE60011895T2 (pt)
DK (1) DK1178982T3 (pt)
ES (1) ES2226844T3 (pt)
HK (1) HK1045305B (pt)
HU (1) HU225894B1 (pt)
IL (2) IL146476A0 (pt)
MX (1) MXPA01011897A (pt)
NO (1) NO20015669L (pt)
NZ (1) NZ515207A (pt)
PL (1) PL200427B1 (pt)
PT (1) PT1178982E (pt)
SI (1) SI1178982T1 (pt)
SK (1) SK16812001A3 (pt)
WO (1) WO2000071534A1 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6376472B1 (en) * 1996-07-08 2002-04-23 Aventis Pharmaceuticals, Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
MY137020A (en) * 2000-04-27 2008-12-31 Abbott Lab Diazabicyclic central nervous system active agents
US6809105B2 (en) 2000-04-27 2004-10-26 Abbott Laboratories Diazabicyclic central nervous system active agents
HUP0200849A2 (hu) * 2002-03-06 2004-08-30 Sanofi-Synthelabo N-aminoacetil-2-ciano-pirrolidin-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
US20040242641A1 (en) * 2003-05-27 2004-12-02 Buckley Michael J. (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent
US7399765B2 (en) 2003-09-19 2008-07-15 Abbott Laboratories Substituted diazabicycloalkane derivatives
US8580842B2 (en) 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
US20080167286A1 (en) 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
US8486979B2 (en) 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
UY30846A1 (es) 2006-12-30 2008-07-31 Abbott Gmbh & Amp Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
BRPI0820668A2 (pt) 2007-12-07 2017-08-22 Abbott Gmbh & Co Kg Derivados de oxindol substituídos por 5-halogênio e seu uso para tratar doenças dependentes de vasopressina
WO2010009775A1 (de) 2007-12-07 2010-01-28 Abbott Gmbh & Co. Kg Carbamat-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
US8703775B2 (en) 2007-12-07 2014-04-22 AbbVie Deutschland GmbH & Co. KG Amidomethyl-substituted oxindole derivatives and the use thereof for the treatment of vasopressin-dependent illnesses
CN102026995B (zh) 2007-12-07 2014-10-29 Abbvie德国有限责任两合公司 5,6-二取代的羟吲哚衍生物和其用途
US8383657B2 (en) 2007-12-21 2013-02-26 Abbott Laboratories Thiazolylidine urea and amide derivatives and methods of use thereof
CN101952252A (zh) * 2008-02-27 2011-01-19 住友化学株式会社 哌啶-3-基氨基甲酸烷基酯的光学拆分方法及其中间体
JP2009256298A (ja) * 2008-03-26 2009-11-05 Sumitomo Chemical Co Ltd ピペリジン−3−イルカーバメート化合物の光学分割方法およびその中間体
JP2011516489A (ja) 2008-03-31 2011-05-26 ユニバーシティ・オブ・サウス・フロリダ 疾患誘発性運動失調症および非運動失調性平衡異常の治療法
WO2009149135A1 (en) 2008-06-04 2009-12-10 Abbott Laboratories Bis (hetero ) aryl substituted isoxazoles for use as neuronal nicotinic receptor modulators
TW201022233A (en) * 2008-11-04 2010-06-16 Organon Nv (Pyrrolidin-2-yl)phenyl derivatives
US9040568B2 (en) 2009-05-29 2015-05-26 Abbvie Inc. Pharmaceutical compositions for the treatment of pain
WO2010151815A2 (en) 2009-06-25 2010-12-29 Abbott Laboratories 3,9-diazaspiro[5,5]undecane amides and ureas and methods of use thereof
UY32826A (es) 2009-08-04 2011-02-28 Takeda Pharmaceutical Compuestos heterocíclicos
CN102936220B (zh) * 2012-11-15 2014-07-02 河北桑迪亚医药技术有限责任公司 一种氨基吡啶boc保护的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4302456A (en) 1977-04-13 1981-11-24 The Upjohn Company Process for therapeutic treatment
FR2459240A1 (fr) 1979-06-21 1981-01-09 Cm Ind Aminopiperidines anorexigenes, procede pour leur preparation, intermediaires dans ledit procede et medicaments qui les contiennent
US4302455A (en) * 1980-04-14 1981-11-24 Merck & Co., Inc. 2-(4-Aminopiperidino)pyrazines
EP0647639A1 (fr) * 1993-10-11 1995-04-12 Sanofi Hétéroarylpipéridines, procédé pour leur préparation et compositions pharmaceutiques les contenant
CA2133855A1 (en) * 1993-10-11 1995-04-12 Marco Baroni Heteroarylpiperidines, process for their preparation and pharmaceutical compositions in which they are present
US5585388A (en) * 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors

Also Published As

Publication number Publication date
SK16812001A3 (sk) 2002-05-09
NO20015669D0 (no) 2001-11-20
HUP0202034A2 (en) 2002-10-28
IL146476A0 (en) 2002-07-25
AU781241B2 (en) 2005-05-12
BR0007229A (pt) 2002-09-10
DE60011895T2 (de) 2005-08-04
CN1192028C (zh) 2005-03-09
ATE270288T1 (de) 2004-07-15
SI1178982T1 (en) 2004-12-31
WO2000071534A1 (en) 2000-11-30
NZ515207A (en) 2003-09-26
JP2003500402A (ja) 2003-01-07
PT1178982E (pt) 2004-11-30
HU225894B1 (en) 2007-12-28
MXPA01011897A (es) 2002-06-21
CN1636990A (zh) 2005-07-13
NO20015669L (no) 2001-11-23
CN1361774A (zh) 2002-07-31
CZ20014127A3 (cs) 2002-06-12
KR20060118618A (ko) 2006-11-23
ES2226844T3 (es) 2005-04-01
HUP0202034A3 (en) 2006-04-28
PL200427B1 (pl) 2009-01-30
HK1045305A1 (en) 2002-11-22
KR100714121B1 (ko) 2007-05-04
EP1178982B1 (en) 2004-06-30
HK1045305B (zh) 2005-04-01
KR100714122B1 (ko) 2007-05-04
AU5016600A (en) 2000-12-12
EP1178982A1 (en) 2002-02-13
CA2373793A1 (en) 2000-11-30
PL352066A1 (en) 2003-07-28
DK1178982T3 (da) 2004-11-08
EP1428824A1 (en) 2004-06-16
DE60011895D1 (de) 2004-08-05
KR20060110877A (ko) 2006-10-25
IL190780A0 (en) 2008-11-03

Similar Documents

Publication Publication Date Title
BG106192A (bg) Аминоазацикли, заместени с хетероцикъл, полезни като средства за контролиране на централната нервнасистема
US20080090798A1 (en) Heterocyclic Substituted Aminoazacycles Useful as Central Nervous System Agents
AU773795B2 (en) Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands
AU2001266559C1 (en) Diazabicyclic central nervous system active agents
US7265115B2 (en) Diazabicyclic CNS active agents
US20020151712A1 (en) 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission
MXPA02002115A (es) Compuestos de eter 3-pirrolidiniloxi-3'-piridilico, utiles para controlar la transmision sinaptica quimica. .
US6656958B2 (en) Substituted pyridine compounds useful for controlling chemical synaptic transmission
ZA200109162B (en) Heterocyclic substituted aminoazacycles useful as central nervous system agents.
EP1257535B1 (en) Substituted pyridine compounds useful for controlling chemical synaptic transmission
TW202400580A (zh) 作為配體導向降解劑之bcl6調節劑